ALENDRONATE FOR GLUCOCORTICOID-ASSOCIATED OSTEOPENIA

阿仑膦酸钠治疗糖皮质激素相关骨质减少症

• 批准号: 7607239
• 负责人: CATHERINE M. GORDON
• 金额: $ 0.14万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607239
• 关键词: Adolescent; Alendronate; Caring; Child; Chronic Childhood Arthritis; Computer Retrieval of Information on Scientific Projects Database; Crohn' s disease; Dermatomyositis; Dual-Energy X-Ray Absorptiometry; Fosamax; Funding; Glucocorticoids; Grant; Individual; Institution; Osteoporosis; Research; Research Personnel; Resources; Source; Standards of Weights and Measures; Testing; Ulcerative Colitis; United States National Institutes of Health; Vertebral column

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This trial will test the hypothesis that among children and adolescents with Crohn's disease, ulcerative colitis, systemic-onset juvenile rheumatoid arthritis and juvenile dermatomyositis, treatment of glucocorticoid-associated osteopenia and osteoporosis with 18 months of alendronate (FOSAMAX, Merck & Co., Inc.) will result in greater improvement in mean changes in individual AP spine BMD (gm/cm) determined by dual energy X-ray absorptiometry (DXA) than treatment with 18 months of standard care therapy.

这个子项目是众多研究子项目之一